Feb 8 (Reuters) - Bayer AG
* Says Phase III compass study with rivaroxaban in patients with coronary or peripheral artery disease shows overwhelming efficacy and meets primary endpoint early
* Says Bayer, Janssen and Population Health Research Institute (PHRI) will offer rivaroxaban to study participants in an open-label extension trial
* Says a complete data analysis from this study is expected to be presented at an upcoming medical meeting in 2017 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.